IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α

JA Holmes; T Nguyen; D Ratnam; NM Heerasing; JV Tehan; S Bonanzinga; A Dev; S Bell; S Pianko; R Chen; K Visvanathan; R Hammond; D Iser; F Rusli; W Sievert; PV Desmond; DS Bowden; AJ Thompson

Journal article

IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α

JA Holmes, T Nguyen, D Ratnam, NM Heerasing, JV Tehan, S Bonanzinga, A Dev, S Bell, S Pianko, R Chen, K Visvanathan, R Hammond, D Iser, F Rusli, W Sievert, PV Desmond, DS Bowden, AJ Thompson

Journal of Gastroenterology and Hepatology Australia | WILEY-BLACKWELL | Published : 2013

DOI: 10.1111/jgh.12110

Download PDF

Abstract

Background and Aim: IL28B genotype predicts response to pegylated interferon (peg-IFN)-based therapy in chronic hepatitis C. However, the utility of IL28B genotyping in chronic hepatitis B (CHB) cohorts treated with peg-IFN is unclear. It was investigated whether IL28B genotype is associated with peg-IFN treatment outcomes in a predominantly Asian CHB cohort. Methods: This was a retrospective analysis of CHB patients treated with 48 weeks of peg-IFN monotherapy. IL28B genotype (rs12979860) was determined (TaqMan allelic discrimination kit). Baseline hepatitis B virus (HBV)-DNA, alanine aminotransferase, and liver histology were available. The primary end-points were HBV e antigen (HBeAg) ser..

View full abstract